Active pharmaceutical ingredients market size to grow by USD 88.74 billion from 2022 to 2027: Increasing number of type II DMFs to drive growth - Technavio

NEW YORK, April 25, 2023 /PRNewswire/ -- The active pharmaceutical ingredients market size is forecasted to increase by USD 88.74 billion from 2022 to 2027, at a CAGR of 7.24%, according to the recent market study by Technavio. The growth of the market will be driven by the evolving API manufacturing scenario in developing countries, the increasing number of type II drug master files (DMFs), and the growing need to focus on core competencies. Charts & data tables about market and segment sizes for a historic period (2017-2021) and forecast period (2023-2027) have been covered in this report. Download the Sample Report

Vendor analysis: Vendor offerings -

• Amneal Pharmaceuticals Inc. - The company offers active pharmaceutical ingredients such as Bacitracin Zinc.
• Aurobindo Pharma Ltd. - The company offers active pharmaceutical ingredients such as penicillin and cephalosporins.
• Cadila Pharmaceuticals Ltd. - The company offers active pharmaceutical ingredients such as Zolpidem Tartrate and Pranlukast Hydrate.
• Cipla Ltd. - The company offers active pharmaceutical ingredients such as Abacavir Sulphate.

Technavio has extensively analyzed 15 major vendors, including AbbVie Inc., Amneal Pharmaceuticals Inc., Apotex Inc., Aurobindo Pharma Ltd., Cadila Pharmaceuticals Ltd., Cambrex Corp., Cipla Ltd., Dr Reddys Laboratories Ltd., GlaxoSmithKline Plc, Indena S.p.A., INTERNATIONAL CHEMICAL INVESTORS S.E., Koninklijke DSM NV, Lupin Ltd., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc.

Key benefits for industry players & stakeholders – 

• The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
• It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
• The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Expand operations in the future - To get requisite details, ask for a custom report.

Customer landscape - Analysis of price sensitivity, adoption lifecycle, customer purchase basket, adoption rates, and purchase criteria by Technavio

• One of the core components of the customer landscape is price sensitivity, an analysis of which will help companies refine marketing strategies to gain a competitive advantage. 
• Another key aspect is price sensitivity drivers (purchases are undifferentiated, the purchase is a key cost to buyers, and quality is not important), which range between LOW and HIGH.
• Furthermore, market adoption rates for all regions have been covered.

Get a holistic overview of the market to evaluate and develop growth strategies. Download the Sample

Market segmentation:

• Manufacturing type 
• Captive APIs
• Contract APIs

The captive APIs segment will account for a significant share of market growth during the forecast period. The focus on rising access to affordable medical services has increased the need for access to low-cost medicines and the demand for low-cost APIs. Most innovators engaged in the development of biopharmaceutical products rely on in-house capabilities for manufacturing high-quality APIs. This is because of the increasing emphasis on quality control of APIs and their production facilities. These factors will drive the growth of the captive API segment during the forecast period.

• Type 
• Innovative APIs
• Generic APIs

The innovative APIs segment will account for a significant share of market growth during the forecast period. API is administered intravenously when an infection is severe and other routes may not work effectively. The types of intravenous administration include intravenous injection and PICC line. Infections that can be treated through a brief course of intravenous API include pneumonia, urinary tract infections, intraabdominal infections, gram-negative bacteremia, chronic lung disease, and skin and soft tissue infections. Moreover, prolonged intravenous API courses treat infections of bones and joints and infective endocarditis. Therefore, the increasing incidence of diseases will drive the growth of the innovative APIs segment during the forecast period.

• Geography 
• Asia
• North America
• Europe
• Rest of World (ROW))

Asia is estimated to account for 66% of the growth of the global active pharmaceutical ingredients (API) market during the forecast period. In India, companies are highly skilled in manufacturing drugs according to Good Manufacturing Practice (GMP) standards. They also comply with regulatory requirements of generic-based companies in the US and Europe. In China, manufacturing costs are low. Owing to these factors, the growth potential in the active pharmaceutical ingredients market in APAC will be high during the forecast period.

Market dynamics:

Key drivers:

• Increasing number of type II drug master files (DMFs)
• Evolving API manufacturing scenario in developing countries
• Growing need to focus on core competencies

The number of DMF applications for APIs is rising, and healthcare spending in urban areas is increasing worldwide. DMFs are submitted to the US FDA and contain detailed information about facilities, processes, and materials used in the manufacturing, processing, and packaging of pharmaceuticals. There are five types of DMFs, and type II DMF is the most common. It includes drug substances, substance intermediates, and materials used in manufacturing pharmaceutical products. Pharmaceutical manufacturers rely on API manufacturers to outsource large volumes of APIs. These factors are expected to fuel the growth of the API market during the forecast period. 

Major trends:

• Increasing patent expiries
• Paradigm shift in API manufacturing
• Increasing geriatric population

Patent expiries for various pharmaceutical products are increasing globally, which is creating significant opportunities for generic drug manufacturers to enter the market. Generic drugs are as potent as branded drugs but are inexpensive. Therefore, various major pharmaceutical companies are attracting API manufacturers in emerging markets such as India and China. Biopharmaceutical manufacturing is a capital-intensive, complex, and highly technical process. Therefore, outsourcing biopharmaceutical APIs has become attractive due to the lack of in-house manufacturing capacity of small and medium-sized biotech companies. All these factors are expected to support the growth of the active pharmaceutical ingredients market during the forecast period.

Key challenges:

• Stringent regulatory environment
• High investment cost and concern of huge financial loss
• Capacity utilization constraints

The drug development and approval process is highly regulated based on factors such as safety, efficacy, pharmacological data, pharmacodynamic effects, and drug interactions. If a product does not meet any criteria, the manufacturer may receive a complete response letter (CRL). In addition, small deviations in API can lead to large deviations in clinical trial results. Therefore, the presence of a stringent regulatory environment related to drug development may increase drug failures, which, in turn, can hinder the API market growth during the forecast period. 

To get detailed insights about key market drivers, upcoming trends, and challenges, buy the report

What are the key data covered in this active pharmaceutical ingredients market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the active pharmaceutical ingredients market between 2023 and 2027
• Precise estimation of the size of the active pharmaceutical ingredients market and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the active pharmaceutical ingredients market across Asia, North America, Europe, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of active pharmaceutical ingredients market vendors

Related Reports:

The active and intelligent packaging in pharmaceutical market size is expected to increase by USD 1.00 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 7.71%. This report extensively covers market segmentation by type (active packaging and intelligent packaging) and geography (North America, Europe, APAC, South America, and MEA).

The bioactive wound dressing market size is expected to increase by USD 1.17 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.63%. Furthermore, this report extensively covers market segmentation by type (moist wound care, active wound care, and antimicrobial care) and geography (North America, Europe, Asia, and Rest of World (ROW)).

Gain instant access to 17,000+ market research reports, Subscribe to our Basic Plan billed annually at USD 5000. 
Technavio's SUBSCRIPTION platform

Browse for Technavio health care market reports

Table of contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Manufacturing Type
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022

• 3.4 Market outlook: Forecast for 2022-2027 
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global active pharmaceutical ingredients market 2017 - 2021 
• Exhibit 18: Historic Market Size – Data Table on Global active pharmaceutical ingredients market 2017 - 2021 ($ billion)

• 4.2 By Manufacturing type Segment Analysis 2017 - 2021 
• Exhibit 19: Historic Market Size – By Manufacturing type Segment 2017 - 2021 ($ billion)

• 4.3 By types Segment Analysis 2017 - 2021 
• Exhibit 20: Historic Market Size – By types Segment 2017 - 2021 ($ billion)

• 4.4 Geography Segment Analysis 2017 - 2021 
• Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ billion)

• 4.5 Country Segment Analysis 2017 - 2021 
• Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ billion)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Manufacturing Type

• 6.1 Market segments
• Exhibit 30: Chart on Manufacturing Type - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Manufacturing Type - Market share 2022-2027 (%)

• 6.2 Comparison by Manufacturing Type 
• Exhibit 32: Chart on Comparison by Manufacturing Type
• Exhibit 33: Data Table on Comparison by Manufacturing Type

• 6.3 Captive APIs - Market size and forecast 2022-2027 
• Exhibit 34: Chart on Captive APIs - Market size and forecast 2022-2027 ($ billion)
• Exhibit 35: Data Table on Captive APIs - Market size and forecast 2022-2027 ($ billion)
• Exhibit 36: Chart on Captive APIs - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Captive APIs - Year-over-year growth 2022-2027 (%)

• 6.4 Contract APIs - Market size and forecast 2022-2027 
• Exhibit 38: Chart on Contract APIs - Market size and forecast 2022-2027 ($ billion)
• Exhibit 39: Data Table on Contract APIs - Market size and forecast 2022-2027 ($ billion)
• Exhibit 40: Chart on Contract APIs - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Contract APIs - Year-over-year growth 2022-2027 (%)

• 6.5 Market opportunity by Manufacturing Type 
• Exhibit 42: Market opportunity by Manufacturing Type ($ billion)
• Exhibit 43: Data Table on Market opportunity by Manufacturing Type ($ billion)

7 Market Segmentation by Type

• 7.1 Market segments
• Exhibit 44: Chart on Type - Market share 2022-2027 (%)
• Exhibit 45: Data Table on Type - Market share 2022-2027 (%)

• 7.2 Comparison by Type
• Exhibit 46: Chart on Comparison by Type
• Exhibit 47: Data Table on Comparison by Type

• 7.3 Innovative APIs - Market size and forecast 2022-2027 
• Exhibit 48: Chart on Innovative APIs - Market size and forecast 2022-2027 ($ billion)
• Exhibit 49: Data Table on Innovative APIs - Market size and forecast 2022-2027 ($ billion)
• Exhibit 50: Chart on Innovative APIs - Year-over-year growth 2022-2027 (%)
• Exhibit 51: Data Table on Innovative APIs - Year-over-year growth 2022-2027 (%)

• 7.4 Generic APIs - Market size and forecast 2022-2027 
• Exhibit 52: Chart on Generic APIs - Market size and forecast 2022-2027 ($ billion)
• Exhibit 53: Data Table on Generic APIs - Market size and forecast 2022-2027 ($ billion)
• Exhibit 54: Chart on Generic APIs - Year-over-year growth 2022-2027 (%)
• Exhibit 55: Data Table on Generic APIs - Year-over-year growth 2022-2027 (%)

• 7.5 Market opportunity by Type 
• Exhibit 56: Market opportunity by Type ($ billion)
• Exhibit 57: Data Table on Market opportunity by Type ($ billion)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 59: Chart on Market share by geography 2022-2027 (%)
• Exhibit 60: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 61: Chart on Geographic comparison
• Exhibit 62: Data Table on Geographic comparison

• 9.3 Asia - Market size and forecast 2022-2027 
• Exhibit 63: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
• Exhibit 64: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
• Exhibit 65: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 66: Data Table on Asia - Year-over-year growth 2022-2027 (%)

• 9.4 North America - Market size and forecast 2022-2027 
• Exhibit 67: Chart on North America - Market size and forecast 2022-2027 ($ billion)
• Exhibit 68: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
• Exhibit 69: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 70: Data Table on North America - Year-over-year growth 2022-2027 (%)

• 9.5 Europe - Market size and forecast 2022-2027 
• Exhibit 71: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
• Exhibit 72: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
• Exhibit 73: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 74: Data Table on Europe - Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 
• Exhibit 75: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
• Exhibit 76: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
• Exhibit 77: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 78: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

• 9.7 China - Market size and forecast 2022-2027 
• Exhibit 79: Chart on China - Market size and forecast 2022-2027 ($ billion)
• Exhibit 80: Data Table on China - Market size and forecast 2022-2027 ($ billion)
• Exhibit 81: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 82: Data Table on China - Year-over-year growth 2022-2027 (%)

• 9.8 India - Market size and forecast 2022-2027 
• Exhibit 83: Chart on India - Market size and forecast 2022-2027 ($ billion)
• Exhibit 84: Data Table on India - Market size and forecast 2022-2027 ($ billion)
• Exhibit 85: Chart on India - Year-over-year growth 2022-2027 (%)
• Exhibit 86: Data Table on India - Year-over-year growth 2022-2027 (%)

• 9.9 US - Market size and forecast 2022-2027 
• Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ billion)
• Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ billion)
• Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)

• 9.10 Japan - Market size and forecast 2022-2027 
• Exhibit 91: Chart on Japan - Market size and forecast 2022-2027 ($ billion)
• Exhibit 92: Data Table on Japan - Market size and forecast 2022-2027 ($ billion)
• Exhibit 93: Chart on Japan - Year-over-year growth 2022-2027 (%)
• Exhibit 94: Data Table on Japan - Year-over-year growth 2022-2027 (%)

• 9.11 Germany - Market size and forecast 2022-2027 
• Exhibit 95: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
• Exhibit 96: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
• Exhibit 97: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 98: Data Table on Germany - Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 99: Market opportunity by geography ($ billion)
• Exhibit 100: Data Tables on Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers

• 10.2 Market challenges

• 10.3 Impact of drivers and challenges 
• Exhibit 101: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview

• 11.2 Vendor landscape
• Exhibit 102: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption
• Exhibit 103: Overview on factors of disruption

• 11.4 Industry risks
• Exhibit 104: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 105: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 106: Matrix on vendor position and classification

• 12.3 AbbVie Inc.
• Exhibit 107: AbbVie Inc. - Overview
• Exhibit 108: AbbVie Inc. - Product / Service
• Exhibit 109: AbbVie Inc. - Key news
• Exhibit 110: AbbVie Inc. - Key offerings

• 12.4 Amneal Pharmaceuticals Inc. 
• Exhibit 111: Amneal Pharmaceuticals Inc. - Overview
• Exhibit 112: Amneal Pharmaceuticals Inc. - Business segments
• Exhibit 113: Amneal Pharmaceuticals Inc. - Key news
• Exhibit 114: Amneal Pharmaceuticals Inc. - Key offerings
• Exhibit 115: Amneal Pharmaceuticals Inc. - Segment focus

• 12.5 Aurobindo Pharma Ltd. 
• Exhibit 116: Aurobindo Pharma Ltd. - Overview
• Exhibit 117: Aurobindo Pharma Ltd. - Product / Service
• Exhibit 118: Aurobindo Pharma Ltd. - Key offerings

• 12.6 Cadila Pharmaceuticals Ltd. 
• Exhibit 119: Cadila Pharmaceuticals Ltd. - Overview
• Exhibit 120: Cadila Pharmaceuticals Ltd. - Product / Service
• Exhibit 121: Cadila Pharmaceuticals Ltd. - Key offerings

• 12.7 Cipla Ltd.
• Exhibit 122: Cipla Ltd. - Overview
• Exhibit 123: Cipla Ltd. - Business segments
• Exhibit 124: Cipla Ltd. - Key news
• Exhibit 125: Cipla Ltd. - Key offerings
• Exhibit 126: Cipla Ltd. - Segment focus

• 12.8 Dr Reddys Laboratories Ltd. 
• Exhibit 127: Dr Reddys Laboratories Ltd. - Overview
• Exhibit 128: Dr Reddys Laboratories Ltd. - Business segments
• Exhibit 129: Dr Reddys Laboratories Ltd. - Key offerings
• Exhibit 130: Dr Reddys Laboratories Ltd. - Segment focus

• 12.9 GlaxoSmithKline Plc
• Exhibit 131: GlaxoSmithKline Plc - Overview
• Exhibit 132: GlaxoSmithKline Plc - Business segments
• Exhibit 133: GlaxoSmithKline Plc - Key offerings
• Exhibit 134: GlaxoSmithKline Plc - Segment focus

• 12.10 Koninklijke DSM NV
• Exhibit 135: Koninklijke DSM NV - Overview
• Exhibit 136: Koninklijke DSM NV - Business segments
• Exhibit 137: Koninklijke DSM NV - Key news
• Exhibit 138: Koninklijke DSM NV - Key offerings
• Exhibit 139: Koninklijke DSM NV - Segment focus

• 12.11 Lupin Ltd.
• Exhibit 140: Lupin Ltd. - Overview
• Exhibit 141: Lupin Ltd. - Product / Service
• Exhibit 142: Lupin Ltd. - Key news
• Exhibit 143: Lupin Ltd. - Key offerings

• 12.12 Novartis AG
• Exhibit 144: Novartis AG - Overview
• Exhibit 145: Novartis AG - Business segments
• Exhibit 146: Novartis AG - Key offerings
• Exhibit 147: Novartis AG - Segment focus

• 12.13 Pfizer Inc.
• Exhibit 148: Pfizer Inc. - Overview
• Exhibit 149: Pfizer Inc. - Product / Service
• Exhibit 150: Pfizer Inc. - Key news
• Exhibit 151: Pfizer Inc. - Key offerings

• 12.14 Sanofi SA
• Exhibit 152: Sanofi SA - Overview
• Exhibit 153: Sanofi SA - Business segments
• Exhibit 154: Sanofi SA - Key news
• Exhibit 155: Sanofi SA - Key offerings
• Exhibit 156: Sanofi SA - Segment focus

• 12.15 Sun Pharmaceutical Industries Ltd. 
• Exhibit 157: Sun Pharmaceutical Industries Ltd. - Overview
• Exhibit 158: Sun Pharmaceutical Industries Ltd. - Product / Service
• Exhibit 159: Sun Pharmaceutical Industries Ltd. - Key offerings

• 12.16 Teva Pharmaceutical Industries Ltd. 
• Exhibit 160: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 161: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 162: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 163: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 164: Teva Pharmaceutical Industries Ltd. - Segment focus

• 12.17 Viatris Inc.
• Exhibit 165: Viatris Inc. - Overview
• Exhibit 166: Viatris Inc. - Business segments
• Exhibit 167: Viatris Inc. - Key offerings
• Exhibit 168: Viatris Inc. - Segment focus

13 Appendix

• 13.1 Scope of the report

• 13.2 Inclusions and exclusions checklist 
• Exhibit 169: Inclusions checklist
• Exhibit 170: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 171: Currency conversion rates for US$

• 13.4 Research methodology
• Exhibit 172: Research methodology
• Exhibit 173: Validation techniques employed for market sizing
• Exhibit 174: Information sources

• 13.5 List of abbreviations 
• Exhibit 175: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio